Skip to main content
Premium Trial:

Request an Annual Quote

Qlife, Precision Biosensor Announce South Korean Partnership

NEW YORK – Qlife, a Danish medical technology company, said Monday that it has signed a letter of intent with South Korean firm Precision Biosensor that will see point-of-care tests deployed to the Korean market on Qlife's Egoo Health platform.

Under the agreement, Precision Biosensor will register Qlife's Egoo Health platform with the Korean Ministry of Food and Drug Safety. The Daejeon-based in vitro diagnostics company will also market, sell, and distribute the Egoo Health platform for use in primary care settings.

QLife said that it expects South Korean sales to commence in the fourth quarter of this year, and that they will contribute to Qlife’s aim of becoming self-financed during 2025.

QLife CEO Thomas Warthoe said in a statement that Asia is "by far the fastest-growing economy in the world today," and the "interest and demand we see there for implementing new health technologies is something that fits well with our novel Egoo biomarker concept."

QLife's Egoo Health business has been looking to expand its international business in recent years. Last August, it discussed its intent to enter the US market, and in December, it announced a partnership with Hipro Biotechnology to launch the Egoo Health platform in China, and to secure China National Medical Products Administration clearance for it within 12 to 18 months.

The Egoo system consists of a small device, disposable capsules, and software, and can be used at the point of care. Each capsule contains a test for a specific biomarker or virus. The device can perform different types of testing, including molecular and immunoassay testing.